| Document |
Document Title |
|
WO/2023/061617A1 |
The present invention relates to compounds of formula (I), wherein R1 to R3, A, Q1, Q2, W and X are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using th...
|
|
WO/2023/061095A1 |
The present invention relates to the field of medicinal chemistry. Disclosed in the present invention are a 14-chloro-β-elemene nitric oxide donor type derivative, preparation and application thereof in preparing an antitumor drug. The ...
|
|
WO/2023/064880A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/063701A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/062575A1 |
Disclosed herein are certain succinamido derivatives of Formula (I): (I) that inhibit Wemer Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are thereofore useful in treating c...
|
|
WO/2023/058673A1 |
The present disclosure provides: a sulfur-containing compound which has a predetermined structure and is useful for treating or preventing eye diseases such as presbyopia and cataracts; and an agent for treating or preventing eye disease...
|
|
WO/2023/057371A1 |
The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 is -Y-R2; Y is -C1-C6alkylene- wherein one non-terminal -CH2- may be replaced by -N(R3)- or -O- and wherein Y may be substituted by...
|
|
WO/2023/057568A1 |
The invention also relates to a process for synthesizing an ester-containing benzoxazine monomer of formula (I) comprising the following steps consisting of: c) reacting a phenolic acid derivative of formula (II), comprising at least one...
|
|
WO/2023/057548A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
|
|
WO/2023/059899A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
|
WO/2023/051134A1 |
The present invention relates to an organometallic iridium compound and an application thereof. The organometallic iridium compound has a general formula of Ir(La)(Lb)(Lc), wherein La has the structure as shown in formula (1), and Lb has...
|
|
WO/2023/049963A1 |
The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy. Formula (I) wherein A is selected from the group consisting of CO2R1, and PO3R1; B is selected from the group ...
|
|
WO/2023/053009A1 |
The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/053007A1 |
The present invention relates to dioxazines, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/055178A1 |
The present invention provides: a novel piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for the prevention or treatment of diseases rel...
|
|
WO/2023/052593A1 |
The invention concerns compounds having antiviral activity, in particular having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising th...
|
|
WO/2023/049364A1 |
The present disclosure is directed to compounds of formula (I):; wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates ...
|
|
WO/2023/046664A1 |
The invention relates to novel compounds of the general formula (l-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2023/049367A1 |
The present disclosure is directed to compounds of formula (I):, wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts...
|
|
WO/2023/047416A1 |
The present invention relates to a novel process for preparation of an isoxazole compound of formula (I) by reacting a compound of formula (II) with a compound of formula (III). wherein, n is 0, 1 or 2; 10 R1, R2, R3 and R4 are independe...
|
|
WO/2023/049369A2 |
The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable sal...
|
|
WO/2023/048118A1 |
A purpose of the present invention is to provide a compound which is suitable for use as a material for the capping layer of an organic EL element, has a high refractive index in the wavelength range of 450-750 nm, and has a low extincti...
|
|
WO/2023/046698A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2023/046133A1 |
Disclosed are a dihydropyrimidine compound, a preparation method therefor and an application thereof, belonging to the technical field of pharmaceutical chemistry. The present invention relates to a dihydropyrimidine compound, the struct...
|
|
WO/2023/045978A1 |
Provided are a 2,6-piperidinedione compound and an application thereof. Particularly provided are a compound represented by formula (II), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/049691A1 |
Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are CDK7 inhibitors that are useful for treating conditions characterized ...
|
|
WO/2023/046055A1 |
Disclosed in the present invention are a substituted heterocyclic compound containing an α-ketone framework, and the use thereof, which relate to the field of medicinal chemistry. Specifically disclosed are a substituted heterocyclic co...
|
|
WO/2023/049888A1 |
The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed her...
|
|
WO/2022/170974A9 |
Provided are a compound of formula (I) that inhibit the activity of PARP7, a stereoisomer thereof, a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, an intermediate to prepare the compound, a process to prep...
|
|
WO/2023/049199A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including autoimmune diseases, inflammatory conditions a...
|
|
WO/2023/041756A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
|
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/043938A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a sulfamide RNR inhibitor disclosed herein.
|
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
|
WO/2023/043836A1 |
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, dis...
|
|
WO/2023/041055A1 |
Disclosed is a class of KIF18A inhibitors. Specifically, the present invention relates to a compound as represented by general formula (1), a preparation method therefor, and the use of the compound as represented by general formula (1) ...
|
|
WO/2023/044171A1 |
The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...
|
|
WO/2023/043833A1 |
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological...
|
|
WO/2023/043816A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/040537A1 |
The present disclosure relates to the field of pharmaceutical chemistry, and specifically relates to an aminopyrimidine derivative having a structure represented by general formula (I) or general formula (II), a stereoisomer, pharmaceuti...
|
|
WO/2023/041059A1 |
The present invention relates to an octahydropyrazinodiazanaphthyridine dione compound and a crystal form thereof, and specifically relates to a compound as represented by formula (I) and a crystal form thereof.
|
|
WO/2023/041757A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, A1, A2, A3, A4, A5, A6, L and W are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2023/043284A1 |
The invention provides novel substituted heterocyclic rings represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compou...
|
|
WO/2023/038815A1 |
Disclosed herein is method for treating and/or preventing a cytokine release-related condition associated with infection by a respiratory virus, e.g., COVID-19 or influenza. In certain embodiments, the method may comprise administering a...
|
|
WO/2023/036093A1 |
A class of ketoamide derivatives and an application thereof are disclosed. Specifically disclosed are a compound of formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/036821A1 |
The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds...
|
|
WO/2023/039278A1 |
The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
|
|
WO/2023/030335A1 |
The present invention provides a compound as a TYK2/JAK1 pseudokinase domain inhibitor, and synthesis and use methods. Specifically, provided is a compound or a pharmaceutically acceptable salt thereof, the compound is as represented by ...
|
|
WO/2023/031308A1 |
The present invention relates to novel substituted aryl sulfonamide compounds, to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of substituted ...
|
